MPM Asset Management LLC

-

Assets, Funds, Holdings

Home | Sign Up | Log In
New Features
Latest Fund Raises
Related People
Fund Service Providers
Startup & Company Raises
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Keyboard
MPM Asset Management LLC
CRD #148467
SEC #801-106989
CIK #0001496086, 0001263048
AUM 3,558.1 M (2026-04-28)
Employees 50 (54% Investors, 0% Brokers)
Fees
Minimum
Phone617-425-9200
Address399 Boylston Street
Boston, MA 02116
Source [IAPD] [EDGAR] [Website] [Twitter] [LinkedIn]
Total AUM ($B)
4.03.22.41.60.80.02009201520212027
Fees and Compensation — Form ADV Part 2A (4/28/2026) [Brochure]
Item 5.    Fees and Compensation

The Adviser or its affiliates generally receive Advisory Fees, Performance Allocations, and
Carried Interest (each as defined below) or similar performance-based remuneration from a Fund.
Performance Allocations, Carried Interest and similar performance-based remuneration is
collectively referred to in this brochure as “Incentive Compensation”. A Fund, and/or its portfolio
companies may also reimburse the Adviser and its affiliates or its employees, advisors, or
consultants for certain expenses and/or make other payments to the Adviser or its affiliates or its
employees, advisors, or consultants for services provided to the portfolio companies which, in
certain circumstances, reduces the Advisory Fees payable to the Adviser. Additionally, consistent
with the Organizational Documents of a Fund, the Fund typically bears certain out-of-pocket
expenses incurred by the Adviser in connection with the services provided to the Fund and/or the
portfolio companies. Further details about certain common fees and expenses are set forth below.

Advisory Fees

As compensation for investment supervisory services rendered to the Funds, the Adviser receives
from each such Fund an advisory fee (each, an “Advisory Fee”) typically calculated based on
committed capital or the value of assets, as determined by the Adviser, with respect to such Fund.
Advisory Fees may be reduced during the life of a Fund. The precise amount of, and the manner
and calculation of, the Advisory Fees for each Fund are established by the Adviser and are set
forth in such Fund’s Organizational Documents. The Advisory Fees and other fees and
distributions described herein are generally subject to modification, waiver or reduction by the
Adviser in its sole discretion, both voluntarily and on a negotiated basis with selected investors via
side letter and other arrangements, which may not be disclosed to other investors in the same Fund.
The fee structures described herein may be modified from time to time. Fees may differ from one
Fund to another, as well as among investors in the same Fund. Unless otherwise agreed with a
Fund’s investors, Advisory Fees will continue to be payable during any term extensions.

The Advisory Fees paid by certain Funds will generally be reduced by (1) the fees incurred by the
Adviser in connection with the organization of such Fund that exceed a limit specified in such
Fund’s Organizational Documents and/or (2) certain Other Fees (as defined and described in more
detail below) received by the Adviser or its affiliates. The amount and manner of such reduction,
if any, is set forth in the Organizational Documents of the applicable Fund.

Advisory Fees vary Fund by Fund and are either payable quarterly or monthly in advance. There
are also legacy Advisory Fee and Incentive Compensation structures for certain Funds that are
generally no longer available to new investors.

Certain investors in the Funds that are employees, business associates and other “friends and
family” of the Adviser, its affiliates or their personnel or former personnel, including any related
entity established by any of the foregoing, such as trusts, charitable programs, endowments or
related programs, family investment vehicles and other estate planning vehicles (collectively,
“Adviser Investors”) will not typically pay Advisory Fees in connection with their investment in
a Fund. Furthermore, Adviser Investors do not generally bear any expenses incurred in making an
investment and, as a result, such expenses are generally borne by the Funds. Adviser Investors will
only bear those expenses specifically allocated solely to an Adviser Investor vehicle (for instance,

administrative fees, tax preparation fees, state filing fees and similar fees). In addition, the Adviser
has in the past and may from time to time in the future establish certain investment vehicles through
which certain Adviser Investors, other “friends of the firm,” or other persons may invest alongside
one or more Funds in one or more investment opportunities. Such co-investment vehicles generally
will not pay Advisory Fees or Incentive Compensation.

In addition, as set forth in the Organizational Documents of the applicable Fund, the Adviser and
its affiliates, may utilize a “deemed contribution” or “cashless commitment” to satisfy any
obligation of the Adviser and certain employees and affiliates of the Adviser to invest in and
alongside such Fund and will only be paid in cash if such Fund does not return capital contributed
by the limited partners. This “deemed contribution” or “cashless commitment” could result in
acceleration of investor capital contributions.

The Adviser or an affiliated General Partner deducts Advisory Fees and Incentive Compensation
directly from Fund assets and does not bill investors in the Funds.

Upon termination of an Advisory Agreement, prepaid Advisory Fees are processed in accordance
with the terms of the applicable agreement.

Performance Allocations

The affiliated General Partner of certain Funds that engage in the trading of public securities
receives performance-based compensation generally equal to either 15% or 20% annually of the
excess net profit over net losses related to public securities, subject to a high-water mark (the
“Performance Allocation”). The Performance Allocation is generally made to the respective
General Partner at the end of each year or sooner upon withdrawals by investors. Please see Item
6 below regarding Performance Allocation.

Carried Interest Payments

With respect to certain Funds, a portion of the profits of each such Fund is distributed to its General
Partner, if any, as “carried interest” (the “Carried Interest”), generally equal to 20%. Please see
Item 6 below regarding Carried Interest.

Other Fees and Expense Reimbursement

Other Fees

In addition to the Advisory Fees and Incentive Compensation, the Adviser and its affiliates receive
...
Account Minimums and Types of Clients — Form ADV Part 2A (4/28/2026) [Brochure]
Item 7.    Types of Clients

The Adviser currently provides investment supervisory services to the Funds. Investment advice
is provided directly to the Funds (subject to the direction and control of the General Partner or
board of directors of each such Fund, if applicable) and not individually to investors in such Fund.

Interests in the Funds are offered pursuant to applicable exemptions from registration under the
Securities Act and the 1940 Act. Investors in the Funds are generally “qualified purchasers” as
defined in the 1940 Act, and may include, among others, public pension plans, corporate pension
plans, endowments, private pension plans, foundations, insurance companies, fund-of-funds,
family offices, Operations Support Providers, Entrepreneur Partners, other institutional investors,
and high-net worth individuals.

The Adviser does not have a minimum size for a Fund, but minimum investment commitments
may be established for investors in the Funds. The General Partner or board of directors of each
Fund may, in its sole discretion, permit investments below the minimum amounts set forth in the
Organizational Documents of such Fund.
Sector Form 13F Holdings Value ($M)
Entrada Therapeutics Inc 25.4
Dyne Therapeutics Inc 8.6
Werewolf Therapeutics Inc 8.5
 
 
 
 
 
 
 
 
Holdings by Sector ($M)
80064048032016002012201620212026
Type Form D Funds Date Sold AUM
HF MPM Bioimpact Innovations Equities Master LP [2025-03-31] 131.1 M 253.9 M
Filed 2025-06-27 (D/A) · Exemption 3(c)(7), 506(b), 3(c) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
Other New Technologies and Virology Fund LP 2025-03-31 140.2 M
VC MPM BioVentures 2022 LP [2023-03-30] 351.0 M 350.7 M
Filed 2023-06-01 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Commission $1,050,000 · Revenue Decline to Disclose
Other Oncology Impact Fund 2 LP [2020-11-17] 326.8 M 1,002.8 M
Filed 2021-11-22 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Commission $11,919,100 · Revenue Decline to Disclose
HF Bioimpact Equities Master Fund LP [2020-03-31] 2.6 M 90.9 M
Filed 2026-03-10 (D/A) · Exemption 506(b) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
VC MPM Asset Management Investors 2002 Bviii LLC 2018-03-30 0.0 M
VC MPM Asset Management Investors 2003 Bviii LLC 2018-03-30 1.4 M
VC MPM Asset Management Investors 2005 Bviii LLC 2018-03-30 0.2 M
VC MPM Asset Management Investors BV2014 LLC 2018-03-30 4.0 M
VC MPM Asset Management Investors BV2018 LLC [2018-03-30] 7.5 M 10.5 M
Filed 2018-11-09 (D) · Exemption 506(b), 3(c)(1) · Remaining Indefinite · Duration One year or less · Net Assets Decline to Disclose
View All
AUM Breakdown Accounts AUM ($B)
By Client Type
(a) Individuals (other than high net worth individuals) 0 0.0
(b) Individuals (high net worth individuals) 0 0.0
(c) Banking or thrift institutions 0 0.0
(d) Investment companies 0 0.0
(e) Business development companies 0 0.0
(f) Pooled investment vehicles 23 3.6
(g) Pension and profit sharing plans 0 0.0
(h) Charitable organizations 0 0.0
(i) State or municipal government entities 0 0.0
(j) Other investment advisers 0 0.0
(k) Insurance companies 0 0.0
(l) Sovereign wealth funds and foreign official institutions 0 0.0
(m) Corporations or other businesses not listed above 0 0.0
(n) Other 0 0.0
Total 23 3.6
By Discretionary
Discretionary 23 3.6
Non-Discretionary 0 0.0
Total 23 3.6
By Non-United States Persons
Non-United States Persons 2.0
United States Persons 1.6
Total 23 3.6
Form D Directors Role # Filings # Firms 2011 - 2026
Amber Ramsey Director 72 30
Nicole Ramroop Director 43 19
Alan Kelly Director 39 17
Bridget Kidner Director 7 4
Howard Rubin Director, Executive Officer 11 3
Bronson Crouch Director 6 3
Todd Foley Director, Executive Officer 42 2
Luke Evnin Director, Executive Officer, Promoter 33 2
James Scopa Director, Promoter 28 2
Ansbert Gadicke Director, Executive Officer, Promoter 27 2
View All
EDGAR Form CIK 2011 - 2026
13F-HR [0001263048]
3 [0001263048]
4 [0001263048]
Firm Profile (Form ADV)
ServesInstitutional
Fund TypesHedge Fund, Private Equity
Form 3/4/5 Subject 2011 - 2026
Oncology Impact Private Investment Fund 2 LP
MPM Asset Management LLC
Gadicke Ansbert
Aktis Oncology Inc
Oncology Impact Fund Cayman Management LP
MPM Oncology Innovations Fund LP
Werewolf Therapeutics Inc
MPM BioImpact LLC
UBS Oncology Impact Fund LP
MPM Oncology Innovations Fund GP LLC
View All
Insider Transaction (Form 3/4/5) Date Action Shares Price Value ($)
Aktis Oncology Inc AKTS
Common Stock
2026-01-12 Buy 1,112,777 $18.00 20,029,986
Aktis Oncology Inc AKTS
Series B Redeemable Convertible Preferred Stock · derivative
2026-01-12 Conversion 6,000,000 $0.00
Aktis Oncology Inc AKTS
Common Stock
2026-01-12 Conversion 5,914,197
Aktis Oncology Inc AKTS
Common Stock
2026-01-12 Conversion 1,577,119
Aktis Oncology Inc AKTS
Common Stock
2026-01-12 Conversion 1,314,262
Aktis Oncology Inc AKTS
Series A Redeemable Convertible Preferred Stock · derivative
2026-01-12 Conversion 22,500,000 $0.00
Aktis Oncology Inc AKTS
Series Seed Redeemable Convertible Preferred Stock · derivative
2026-01-12 Conversion 5,000,000 $0.00
Werewolf Therapeutics Inc HOWL
Common Stock
2025-12-04 Sell 83,230 $0.97 80,733
Werewolf Therapeutics Inc HOWL
Common Stock
2025-12-03 Sell 57,225 $0.87 49,786
Werewolf Therapeutics Inc HOWL
Common Stock
2025-12-02 Sell 59,277 $0.89 52,757
Werewolf Therapeutics Inc HOWL
Common Stock
2025-12-01 Sell 60,917 $0.94 57,262
Werewolf Therapeutics Inc HOWL
Common Stock
2025-11-28 Sell 20,277 $0.99 20,074
Werewolf Therapeutics Inc HOWL
Common Stock
2025-11-26 Sell 60,733 $0.98 59,518
Werewolf Therapeutics Inc HOWL
Common Stock
2025-11-25 Sell 42,533 $0.92 39,130
Werewolf Therapeutics Inc HOWL
Common Stock
2025-11-24 Sell 88,802 $0.98 87,026
Werewolf Therapeutics Inc HOWL
Common Stock
2025-11-21 Sell 64,331 $0.83 53,395
Werewolf Therapeutics Inc HOWL
Common Stock
2025-11-20 Sell 41,152 $0.89 36,625
Werewolf Therapeutics Inc HOWL
Common Stock
2025-11-19 Sell 66,324 $0.94 62,345
Werewolf Therapeutics Inc HOWL
Common Stock
2025-11-18 Sell 52,627 $0.93 48,943
Werewolf Therapeutics Inc HOWL
Common Stock
2025-11-17 Sell 57,061 $0.95 54,208
showing 20 of 95 most recent transactions
Related Firms State AUM
MPM Asset Management LLC
MA 3,558.1 M
MPM Oncology Impact Management LP
MA
Comparable Firms State AUM
Anchorage Capital Group LLC
NY 3,707.6 M
Resource Capital Investment Corporation
CA 3,706.7 M
Boussard & Gavaudan Investment Management LLP
3,679.1 M
Soleus Capital Management LP
CT 3,663.3 M
Victory Park Capital Advisors LLC
IL 3,647.8 M
First Sentier Investors Australia Infrastructure Managers PTY
3,638.1 M
Axar Capital Management LP
NY 3,598.9 M
Sycamore Tree Capital Partners LP
TX 3,539.6 M
Deer Park Road Management Company LP
CO 3,515.8 M
Hill Path Capital LP
NY 3,408.2 M
Terms | Privacy | Providers | Companies | Guide
tony@aum13f.com